Grant Private Wealth Management Inc Acquires 15,920 Shares of Abbott Laboratories $ABT

Posted by Geri Gentry on Aug 5th, 2026

Grant Private Wealth Management Inc lifted its stake in Abbott Laboratories (NYSE:ABT – Free Report) by 362.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,311 shares of the healthcare product maker’s stock after purchasing an additional 15,920 shares during the period. Abbott Laboratories accounts for approximately 0.8% of Grant Private Wealth Management Inc’s holdings, making the stock its 22nd largest position. Grant Private Wealth Management Inc’s holdings in Abbott Laboratories were worth $1,843,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of ABT. Nia Impact Advisors LLC increased its position in Abbott Laboratories by 2.2% in the second quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock worth $504,000 after buying an additional 79 shares in the last quarter. Clayton Financial Group LLC lifted its position in shares of Abbott Laboratories by 1.4% during the 4th quarter. Clayton Financial Group LLC now owns 6,217 shares of the healthcare product maker’s stock valued at $779,000 after buying an additional 84 shares in the last quarter. Raleigh Capital Management Inc. grew its stake in shares of Abbott Laboratories by 3.9% during the 4th quarter. Raleigh Capital Management Inc. now owns 2,287 shares of the healthcare product maker’s stock valued at $287,000 after acquiring an additional 85 shares during the period. Riggs Asset Managment Co. Inc. increased its holdings in Abbott Laboratories by 9.3% in the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 1,031 shares of the healthcare product maker’s stock worth $140,000 after acquiring an additional 88 shares in the last quarter. Finally, GHP Investment Advisors Inc. increased its holdings in Abbott Laboratories by 0.3% in the 4th quarter. GHP Investment Advisors Inc. now owns 29,411 shares of the healthcare product maker’s stock worth $3,685,000 after acquiring an additional 92 shares in the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ABT. Benchmark lowered their price target on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, April 17th. BTIG Research raised their price objective on shares of Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a research report on Friday, July 17th. UBS Group lowered their target price on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $130.00 target price on shares of Abbott Laboratories in a report on Friday, July 17th. Finally, Bank of America cut their price target on Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $118.17.

View Our Latest Stock Report on Abbott Laboratories

Abbott Laboratories Trading Down 1.4%

Shares of ABT opened at $105.58 on Wednesday. The firm has a market cap of $182.69 billion, a P/E ratio of 34.17, a price-to-earnings-growth ratio of 2.07 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49. The company has a 50 day simple moving average of $94.23 and a two-hundred day simple moving average of $100.20.

Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The firm had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. Abbott Laboratories’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be given a dividend of $0.63 per share. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.4%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 81.55%.

Abbott Laboratories Company Profile

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.